share_log

JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125

JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125

JMP證券維持藍圖藥物的市場跑贏大盤,將目標股價上調至125美元
Benzinga ·  05/03 15:02

JMP Securities analyst Reni Benjamin maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and raises the price target from $114 to $125.

JMP證券分析師雷尼·本傑明維持Blueprint Medicines(納斯達克股票代碼:BPMC)的市場跑贏大盤,並將目標股價從114美元上調至125美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論